Acrobiosystems Co

Acrobiosystems Co Receivables

The Accounts Receivable of Acrobiosystems Co (301080.SZ) as of Nov 21, 2026 is 100.34 M CNY. In the previous year, Accounts Receivable was 74.29 M CNY — a change of 35.06% (higher).

Receivables

100.34 MCNY

YoY

35.06%

Last updated:

Accounts Receivable of Acrobiosystems Co is 2024 100.34 M CNY. Accounts Receivable of Acrobiosystems Co was 2023 74.29 M CNY. It decreases by 35.06% higher compared to the previous year.

The Acrobiosystems Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
9.14 M CNY
Jan 1, 2019
16.17 M CNY
Jan 1, 2020
31.28 M CNY
Jan 1, 2021
49.90 M CNY
Jan 1, 2022
61.87 M CNY
Jan 1, 2023
74.29 M CNY
Jan 1, 2024
100.34 M CNY
The Acrobiosystems Co Receivables history
YEARReceivablesYoY
100.34 MCNY+35.06%
74.29 MCNY+20.07%
61.87 MCNY+24.00%
49.90 MCNY+59.52%
31.28 MCNY+93.44%
16.17 MCNY+77.00%
9.14 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Accounts Receivable of Acrobiosystems Co is 100.34 M CNY in 2024.

Accounts Receivable of Acrobiosystems Co changed from 74.29 M CNY to 100.34 M CNY, representing a 35.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co